NeuroDerm Reports Start Of Patient Enrollment In Phase II Trial Of ND0612H

(RTTNews) - NeuroDerm Ltd. (NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system disorders, Wednesday reported the start of patient enrollment in a first efficacy trial of ND0612H, the company's continuously administered subcutaneous levodopa/carbidopa solution.

This treatment is intended to be an alternative to current treatments for patients with advanced Parkinson's disease that require surgical intervention.

The multicenter international phase II clinical study will compare the efficacy, safety and tolerability of ND0612H to the baseline oral standard of care.

ND0612H, administered through a belt pump, is designed to deliver steady LD/CD levels and improve motor fluctuations that cannot be adequately controlled with oral therapy and might otherwise require surgical intervention.